PET-guided External Beam Radiotherapy in Differentiated Thyroid Cancer

N/ACompletedNCT03191643

IRCCS Azienda Ospedaliero-Universitaria di Bologna16 enrolled

Overview

Description of the role of a post-operative external beam radiotherapy in patients with differentiated thyroid cancer.

The role of post-operative external beam radiotherapy (EBRT) in differentiated thyroid cancer is still discussed considering the low clinical aggressiveness and the availability of ablative 131Iodine therapy. However, there is a subgroup of tumors which lose the ability to capture Iodine over time. This study wants to describe the role of a post-operative external beam radiotherapy in patients with differentiated thyroid cancer.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Differentiated Thyroid Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * detectable thyroglobulin (Tg), * negative post-metabolic radiotherapy whole body scintigraphy, * no surgical indications. Exclusion Criteria: * prior radiotherapy in the head and neck area * pregnancy

Outcomes

Primary Outcomes

Progression free survival (PFS)

Progression-free survival (PFS) after radiotherapy is evaluated with CT-scan and 18F FDG PET-scan. Also laboratory tests are performed (HTG serum level evaluation in case of biochemical recurrence).

Time frame: 6 months

Secondary Outcomes

toxicities

Acute and late toxicities after radiotherapy are assessed with CTCAE v. 4.03 and EORTC-RTOG scales, respectively.

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.